IN8bio, Inc. (NASDAQ:INAB), a biotechnology firm specializing in cancer therapies, has been granted an additional 180 days to comply with Nasdaq's minimum bid price rule, as per a recent SEC filing.

As a result, the Company’s shares will remain listed on the Nasdaq Capital Market. In addition, as it relates to Listing Rule 5550(a)(2) (the “Bid Price Rule”), the Staff has determined that ...

Median returns three months post IPO 2024 performance (the green line in Chart 5) were much better than the last two years (purple and pink lines). Importantly, 2024 IPOs as a group have so far held ...

Technologies announced that it has regained compliance with the Nasdaq Capital Market’s continued listing standard for ...

it was found that the company did not meet the Bid Price Rule requirements. Despite the notification, the company’s common stock listing on The Nasdaq Capital Market remains unaffected at this ...

Nasdaq reported a higher fourth-quarter profit on Wednesday, helped by strong demand for the exchange operator's financial ...

has priced its initial public offering or IPO of 8.8 million shares of common stock at $16.00 each, raising gross proceeds of $140 million. The shares would debut on the Nasdaq Global Market on ...

today announced that it has regained compliance with the Nasdaq Capital Market’s continued listing standard for the minimum share price requirements under Nasdaq Listing Rule 5550(a)(2).

The Company received a letter on February 3, 2025 from the Listings Qualifications Hearing Department of Nasdaq that the Company’s bid price deficiency had been cured and that the Company was in ...